Cargando…

Benefits and limitations of serological assays in COVID-19 infection

Accurate and rapid diagnostic tests are critical for achieving control of coronavirus disease 2019 (covid-19), a pandemic illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Diagnostic tests for covid-19 fall into two main categories: molecular tests that detect viral RNA...

Descripción completa

Detalles Bibliográficos
Autores principales: Sidiq, Zeeshan, Hanif, M., Dwivedi, Kaushal Kumar, Chopra, K.K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tuberculosis Association of India. Published by Elsevier B.V. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409828/
https://www.ncbi.nlm.nih.gov/pubmed/33308664
http://dx.doi.org/10.1016/j.ijtb.2020.07.034
_version_ 1783568132505337856
author Sidiq, Zeeshan
Hanif, M.
Dwivedi, Kaushal Kumar
Chopra, K.K.
author_facet Sidiq, Zeeshan
Hanif, M.
Dwivedi, Kaushal Kumar
Chopra, K.K.
author_sort Sidiq, Zeeshan
collection PubMed
description Accurate and rapid diagnostic tests are critical for achieving control of coronavirus disease 2019 (covid-19), a pandemic illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Diagnostic tests for covid-19 fall into two main categories: molecular tests that detect viral RNA, and serological tests that detect anti-SARS-CoV-2 immunoglobulins. Reverse transcriptase polymerase chain reaction (RT-PCR), a molecular test, has become the gold standard for diagnosis of covid-19; however, this test has many limitations that include potential false negative results, changes in diagnostic accuracy over the disease course, and precarious availability of test materials. Serological tests have generated substantial interest as an alternative or complement to RT-PCR and other Nucleic acid tests in the diagnosis of acute infection, as some might be cheaper and easier to implement at the point of care. A clear advantage of these tests over RT-PCR is that they can identify individuals previously infected by SARS-CoV-2, even if they never underwent testing while acutely ill. Many serological tests for covid-19 have become available in a short period, including some marketed for use as rapid, point-of-care tests. The pace of development has, however, exceeded that of rigorous evaluation, and important uncertainty about test accuracy remains.
format Online
Article
Text
id pubmed-7409828
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Tuberculosis Association of India. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-74098282020-08-07 Benefits and limitations of serological assays in COVID-19 infection Sidiq, Zeeshan Hanif, M. Dwivedi, Kaushal Kumar Chopra, K.K. Indian J Tuberc Review Article Accurate and rapid diagnostic tests are critical for achieving control of coronavirus disease 2019 (covid-19), a pandemic illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Diagnostic tests for covid-19 fall into two main categories: molecular tests that detect viral RNA, and serological tests that detect anti-SARS-CoV-2 immunoglobulins. Reverse transcriptase polymerase chain reaction (RT-PCR), a molecular test, has become the gold standard for diagnosis of covid-19; however, this test has many limitations that include potential false negative results, changes in diagnostic accuracy over the disease course, and precarious availability of test materials. Serological tests have generated substantial interest as an alternative or complement to RT-PCR and other Nucleic acid tests in the diagnosis of acute infection, as some might be cheaper and easier to implement at the point of care. A clear advantage of these tests over RT-PCR is that they can identify individuals previously infected by SARS-CoV-2, even if they never underwent testing while acutely ill. Many serological tests for covid-19 have become available in a short period, including some marketed for use as rapid, point-of-care tests. The pace of development has, however, exceeded that of rigorous evaluation, and important uncertainty about test accuracy remains. Tuberculosis Association of India. Published by Elsevier B.V. 2020-12 2020-08-06 /pmc/articles/PMC7409828/ /pubmed/33308664 http://dx.doi.org/10.1016/j.ijtb.2020.07.034 Text en © 2020 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Sidiq, Zeeshan
Hanif, M.
Dwivedi, Kaushal Kumar
Chopra, K.K.
Benefits and limitations of serological assays in COVID-19 infection
title Benefits and limitations of serological assays in COVID-19 infection
title_full Benefits and limitations of serological assays in COVID-19 infection
title_fullStr Benefits and limitations of serological assays in COVID-19 infection
title_full_unstemmed Benefits and limitations of serological assays in COVID-19 infection
title_short Benefits and limitations of serological assays in COVID-19 infection
title_sort benefits and limitations of serological assays in covid-19 infection
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409828/
https://www.ncbi.nlm.nih.gov/pubmed/33308664
http://dx.doi.org/10.1016/j.ijtb.2020.07.034
work_keys_str_mv AT sidiqzeeshan benefitsandlimitationsofserologicalassaysincovid19infection
AT hanifm benefitsandlimitationsofserologicalassaysincovid19infection
AT dwivedikaushalkumar benefitsandlimitationsofserologicalassaysincovid19infection
AT choprakk benefitsandlimitationsofserologicalassaysincovid19infection